MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Krystal Biotech Inc

Closed

SectorHealthcare

180.93 3.93

Overview

Share price change

24h

Current

Min

173.7

Max

181.26

Key metrics

By Trading Economics

Income

18M

45M

Sales

7.3M

91M

P/E

Sector Avg

59.9

63.778

EPS

1.53

Profit margin

49.901

Employees

275

EBITDA

12M

43M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+24.95% upside

Dividends

By Dow Jones

Next Earnings

5 May 2025

Market Stats

By TradingEconomics

Market Cap

232M

5.3B

Previous open

177

Previous close

180.93

News Sentiment

By Acuity

12%

88%

14 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Krystal Biotech Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Apr 2025, 23:55 UTC

Hot Stocks

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 Apr 2025, 22:50 UTC

Major Market Movers

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 Apr 2025, 21:08 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 Apr 2025, 21:00 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 Apr 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 Apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Apr 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 Apr 2025, 23:44 UTC

Top News

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 Apr 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 Apr 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 Apr 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 Apr 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Apr 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 Apr 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 Apr 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 Apr 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 Apr 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 Apr 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 Apr 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 Apr 2025, 22:43 UTC

Top News
Acquisitions, Mergers, Takeovers

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 Apr 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 Apr 2025, 21:48 UTC

Top News

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 Apr 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 Apr 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 Apr 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 Apr 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 Apr 2025, 21:04 UTC

Top News

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 Apr 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 Apr 2025, 20:53 UTC

Earnings

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 Apr 2025, 20:52 UTC

Earnings

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer Comparison

Price change

Krystal Biotech Inc Forecast

Price Target

By TipRanks

24.95% upside

12 Months Forecast

Average 218.14 USD  24.95%

High 245 USD

Low 200 USD

Based on 8 Wall Street analysts offering 12 month price targets forKrystal Biotech Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

7

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

N/A / 188.5Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

14 / 386 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.